Immune mediated heparin induced thrombocytopenia (HIT)isa prothrombotic adverse effect of heparin. However, onlyas ubgroup of patients withH IT develops thromboembolic complications.Wea imed to identify risk factors ford eveloping HITassociated thrombosis.We analyzed ar egistryo fp atientsw ith clinical suspicion of HITw ho tested positive using as ensitive functional assay. Patient information was obtainedbyastandardized questionnaire.Bym ultivariate analysist he associationo f age,gender, type of patient population, and magnitude of the plateletcountdecline with the frequency,type (venous or arterial), and temporal pattern of thromboticevents wasassessed. In 408 HITpatientsweobservedpredominanceofvenous thrombosis (2.4:1), with 40% of patients developing apulmonary embolism.
However, in the subgroup of post-cardiovascular surgery patients therew as predominanceo fa rterial thrombosis (1:8.5). The type of arterial thrombosis (limb arteryt hrombosis >thrombotic stroke>myocardial infarction) was the converse of that observed with typicalatherothrombotic clots in non-HIT populations.In59.8% of patients HIT-related thrombosis manifestede ithero nt he same dayap lateletc ountd ecrease >50% wasd ocumented (26.3%)o rb eforet he decrease in platelet counts (33.5%).Themost importantriskfactors forthrombosis were orthopedic/trauma surgery and themagnitude of platelet count decrease.H IT-associated thrombosis occurs in ac onsiderableproportionofpatientsbeforeplateletcounts decrease by morethan 50%.
Introduction
Heparin-induced thrombocytopenia(HIT) is aclinicopathological prothrombotic syndrome caused by an immune response (1) usually to complexes of platelet factor 4(PF4) boundtoheparin (2) . HIT antibodies can activate platelets, whichresults in procoagulant plateletm embrane changes (3)t hat enhance thrombin generation in vivo (4) . In patients whoformhigh levels of platelet-activating HITantibodies (5) , the antibodieslead to thrombocytopenia, and al arge proportion of these patients develop thromboembolic complications (TECs) (6) .
Studies screening symptomatic as well as asymptomatic patients (7) showed thatmost patients whoformanti-PF4/heparin antibodies do not develop clinical HIT,some develop adecrease of plateletc ounts only, and some patients develop associated thrombotic complications.T he reasons for the differencesi n clinical breakthrough of HIT are unknown. We used alarge databaseofHIT patients to identifyrisk factorsfor the development of HIT-associatedTECs.
Materials andmethods
We identifiedall patients referred to our laboratorieswith clinically-suspected HIT whot estedp ositivei naf unctional assay (heparin-induced platelet activation test, HIPA [8] ) in one of two laboratories(Greifswald or Giessen).Asthe patients were identifiedb etween 1994 and 1997 the PF4-heparin ELISAw as not availablea tt hat timef or routine diagnosis. Clinical events prompting analysis of HIT-antibodiesincludedamajor decrease in plateletcounts, or,ifnopreceding platelet count wasavailable, an otherwise unexplainedplateletcount less than 100,000 platelets/µl; newthromboemboliccomplications (TECs) during heparin treatment; skin reactions at the heparin injection site(with or without plateletcount fall);orsystemic (anaphylactic) reactions followingaheparin boluswas given. ApositiveHIPAtest wasdefinedasapositivereaction with platelets of at least2of4 donors at low(0.2 IU/ml)heparin concentrations butnot at high (100 IU/ml)heparin concentrations.Patient characteristics were obtainedbyastandardized questionnaire, filledinbythe treating physician, as described (9 Platelet counts at diagnosis of HITw ere compared to the highestavailablepreceding platelet count,however,the frequenciesofplateletcount monitoring varied between patients. Only TECs occurring after at least 5daysofheparin were regarded as HIT-associated eventsfor the purpose of this study,i.e., thromboses that led to heparin treatment were notconsideredHIT-associated TECs. Thequestionnaire requiredincluding onlyobjectively confirmed TECs (methodsdiffered according to the participating hospitals).
Fordiscrete characteristicschi-squaretestwas used,for continuous parameterst he Wilcoxon test wasa pplied. Using univariate and multiple logistic regression analysis, single and combined effects of gender, age group (due to small numbersa ge group 0-19 years and 20-39y ears were combined), fieldo f underlying disease, and relativedecreaseofplateletcounts, on HITassociatedTECs were assessed. Model fitwas evaluatedby the Hosmer-Lemeshows tatistic and the NagelkerkeRSquare index. Fors tatistical analysis SAS (Version 6.12 and 8e) and SPSS (Version 12.0.1)were used. Thelevel of significancewas definedas0.05 (twotailed).
Results

Genderand age
In 406/408patients genderwas documented (58.9% femaleand 41.2% male; >99% of caucasian origin), 66% were 60 years or older (mean age women64.1 ± 15.4 SD years vs.men 60.7 ± 14.3 SD years); 0-19 years (1.5%); 20-39years (6.9%); 40-59years (25.4%); 60-79years (57.3%); ≥ 80 years (8.9%).
Risk of TECand underlying disease
In amultiple logistic regression analysis (Table 1 ) trauma/orthopedic surgery wasanindependent risk factor fordeveloping HIT associatedT ECs (odds ratio5 .3 [95% CI 2.67 -1 0.68; p<0.001]).
Platelet countdecreaseand riskofthrombosis
In 319patients, plateletcounts before occurrence of HITw ere available. At the time of clinical diagnosis of HIT, adecreasein plateletcounts of at least 50% occurredin271/319 (84.9%)patients. Of the remaining 48 patients, HITwas suspected in 14 patients becauseo fn ew thrombosis without plateletc ount fall > 30% (4.4%), in 20 patients (6.3%)d ue to ap lateletc ount decrease between30% and 50%; and in 14 (4.4%)becauseofone or more of the following: skin lesions at the heparin injection side, acute inflammatoryr eaction posti ntravenous heparin bolus, or an otherwise unexplained reported lowplateletcount during apreviousintervention e.g. coronaryangiographyaweek beforew ithoutc omparison value.T he median plateletc ount nadir was4 1.000/µ l( 25% and 75% quartiles: 23.000/µ la nd 67.000/µ l, respectively). Ther isk to develop aH IT associated TEC wasstrongly correlated to the relativedecreaseinplatelet counts(Table1).
Of the 408 patients, 227 (55.6%) developed4 34 TECs associated with HIT( 1.91 TECs/patient). 101 patients had one TEC (44.5%); 69 patients had 2TECs (30.4%); 41 patientshad 3 TECs (18.1%); and 16 patientsd eveloped moret han 3T ECs (7.1%). In 209 patientswith one or moreTECs,onset of thrombocytopenia and dayo fm anifestation of TECc ould be correlated. In 84 patients (40.2%) platelet countsdecreased by more than5 0% one or more days before the thrombosis manifested. The median timed elay betweenp lateletc ount decrease and manifestation of TEC was3.5 days (25-75% quartile1-7days). In 55 patients (26.3%)thrombocytopenia wasfirst documented on the same dayofmanifestation of thrombosis (Fig. 1) .In70 patients (33.5%)the thrombosis preceded adecreaseofplatelet counts. Among this last group of patients, the median timedelay betweenthrombosis and onset of thrombocytopenia was3days (25-75% quartile 1-6 days) (Fig. 1) .T hus, in almost 60% of patients, HIT-related thrombosis manifestedeitheronthe same dayaplateletcount decrease wasdocumented or earlier.
Table2shows the localization of TECs in 225 patients (in 2 other patients information wasmissing regarding whether alimb TECwas arterial or venous). In 43.6% of patients, apulmonary embolism occurred,and in 36.4% therewas proximaldeep vein thrombosis. Theo verall ratioo fv enous (n=306)t oa rterial (n=126)TECs was2.4 :1 (medicalpatients 2.3 :1; general surgerypatients 1.5 :1; orthopedic/traumasurgery2.9 :1; all other patients 6.6 :1). Howeveri nc ardiovasculars urgeryp atients, a marked predominanc of arterial TECsw as observed (ratio 1: 8.5).
Discussion
The purpose of thisstudy wastoassess risk factorsfor thrombosis in serologicallyconfirmed HIT. We used aretrospectiveapproach due to the lowfrequencyofHIT whichmakes it difficult to find sufficient numbers of patients with eventsinaprospective trial. We examinedage, gender, type of plateletcount decline in relation to the frequency, type,and temporalpattern of thrombosis.
As expected,w ef ound HITt ob ev eryp rothrombotic (10), with 55.6% of patients developingone or more TECs (average 1.92 TECs/patient) and approximately 25% of patients developing three or moreHIT related TECs. Our studyunderscores the predominance of venous TECs (71%)inHIT (10) and that ahigh percentage of these patients will develop pulmonary embolism (43.6%) (11) . Interestingly, we also found am arked predominanceofarterial TECs in patients undergoing cardiovascularsurgery (12) . Further,the rank of frequencyofarterial occlusions waslimb artery occlusions >stroke>MI, whichisthe opposite patternasfound in non-HIT patients with atherothrombosis.
Orthopedic/trauma surgeryi ss hown to be an independent risk factor fort he development of HITa ssociatedt hrombosis (13) ,with an odds ratio of 5.3 (95%CI2.67-10.68; p<0.001).
We furtherconfirmthat the risk for HITrelated TECs is relatedt ot he magnitude of the relative plateletc ount decrease (14) .This further suggests that the degree of the plateletactivating capacity of HITantibodies is linked to the capability of these antibodies to induce HITr elated complications.A sH IT is so prothrombotic,and deepveinthrombosis and pulmonaryembol- In 209 patientswithHIT,thrombosis, and thrombocytopenia (>50%plateletcount fall),the daythe thrombosis occurredwas definedasday 0. In thefigurethe daywhenaplateletcount decrease >50%was first documented in themedical record is plotted.In40.2% of patientsthe platelet countdecrease preceded thethromboticcomplication(left partofthe figure; patientswithplateletcount decrease up to 7daysearlier aregiven in thefigure, in 8.6% of patientsplateletcounts decreasedevenmorethan aweek before thethrombosisoccurred).In 26.3% of patientsthe platelet countdecrease was first apparentatthe same daythe thrombosis occurred(day0;middle columnofthe figure). In 33.5% of patientsthe thrombosis manifestedbeforethe platelet counts decreased(right partofthe figure; in 3.9% of patientsthrombosis occurredmorethan 7daysbeforethe platelet countdecrease). Thus in almost 60% of patients, thethrombosisoccurredbeforeoronthe same daythe platelet countfall greater than 50% was documented. ism are very frequent complications,t he present study further corroboratest hat routine screening for thrombosis (e.g. by duplexsonography) should be performed in allpatients with confirmed or stronglysuspected HIT, even if the patient is asymptomatic for venous thromboembolism (15) .A sH IT occurs predominantlyi ne lderlyp atients, potentialr enal impairment should be consideredfor dosing of alternative anticoagulants, especiallyfor lepirudin (16) to avoid bleeding. Perhapsthe most surprising finding is that in almost 60% of patients with HITassociatedthrombosis, the thrombosis either preceded or occurredo nt he same dayt hat thrombocytopenia wasfirst documented. In 33.5%ofpatients, thrombotic complications manifestbefore amajor decreaseinplateletcounts occurred, withthe diagnosis of HITbeing made onlywhen the platelet counts subsequentlyd ecreased over the next fewd ays. Therefore it seemsreasonable to include HITinthe differential diagnosis in all patients whodevelop anew TEC in the typical time windowofHIT,i.e. after 5ormore days after starting heparin(17), whether or notamajor drop in plateletcount occurred. It is interesting to note that in ap rospectivet rial (11,1 8) with dailyp lateletc ount monitoring in post-orthopedic surgeryp atients receiving heparin,i n4o f1 3H IT patients (30.7%), the thrombosis also occurred beforep lateletc ounts decreasedb y >50%, whichisinline with our largeretrospectivestudy.
Therefore,e venp lateletc ount monitoring mayn ot necessarilyavoid allHIT related thrombosis. This underscores the importanceofavoiding this complication by using the less HIT-inducing low-molecular-weight-heparinp reparations,w here otherwise clinicallyappropriate (18, 19) .
